Response assessment to First Line Chemotherapy with VCD Versus VDR in Diagnosed Cases of Multiple Myeloma at CMH Rawalpindi

Raishma; Mussavir Hussain Bangash; Madiha  Sajjad; Muhammad Nadeem; Mansoor  Zeeshan; Faisal  Mehmood

doi:10.51253/pafmj.v76i5.11973

Authors

Raishma Department of Medical Oncology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Mussavir Hussain Bangash Department of Medical Oncology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Madiha Sajjad Department of Medical Oncology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Muhammad Nadeem Department of Medical Oncology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Mansoor Zeeshan Department of Medical Oncology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Faisal Mehmood Department of Medical Oncology, Combined Military Hospital, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i5.11973

Keywords:

Bortezomib, Lenalidomide, Dexamethasone, VCD regimen, VDR regimen, Multiple Myeloma; Response assessment.

Abstract

Objective: To compare response to first line chemotherapy Bortezomib, Lenalidomide and Dexamethasone (VDR) and Bortezomib, Cyclophosphamide and Dexamethasone (VCD) in diagnosed cases of multiple myeloma at CMH Rawalpindi.

Study Design: Prospective comparative study.

Place and Duration of Study: Medical Oncology Department, Combined Military Hospital Rawalpindi, Pakistan Aug 2023 to Feb 2024.

Methodology: This study was carried out on a cohort of 100 multiple myeloma patients classified as high-risk candidates based on the International Scoring System (ISS) with a score of III. Upon diagnosis, the patients were stratified into two Groups. Group-I received a combination of Bortezomib, Lenalidomide and Dexamethasone, (VDR), whereas Group-II recieved Bortezomib, Cyclophosphamide and Dexamethasone (VCD). The efficacy of treatment response and the occurrence of treatment-related adverse effects were evaluated and compared between the two Groups after minimum of four-month treatment period.

Results: The final analysis included 100 multiple myeloma patients, with a median age of 37.50 and range 41 years. Among these patients, 63 (63%) were male, and 37 (37%) were female. Number of patients in Group I, which underwent VDR was 51(51%, while in Group II 49 (49%) received VCD treatment. Statistically significant difference was observed in the treatment response, with a notably superior response in VDR treatment compared to those receiving VCD treatment (p-value<0.001).

Conclusion: Patients receiving treatment with Bortezomib, Dexamethasone, and Lenalidomide (VDR) exhibited superior treatment response as compared to Bortezomib, Cyclophosphamide and Dexamethasone(VCD). However, adverse effects did not show a significant difference between the two treatment Groups.

Downloads

Download data is not yet available.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71(1): 7-33.

http://doi.org/10.3322/caac.21669

2. Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 2020; 95(6): 672-690.

http://doi.org/10.1002/ajh.25764

3. Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals 2023; 16(3): 415. http://doi.org/10.3390/ph16030415

4. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022; 97(8): 1086-1107. http://doi.org/10.1002/ajh.26590

5. Bobin A, Leleu X. Recent advances in the treatment of multiple myeloma: a brief review. Fac Rev 2022; 11(3): 28.

http://doi.org/10.12703/r/11-28

6. Marneni N, Chakraborty R. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. Curr Hematol Malig Rep 2021; 16(2): 148-161.

http://doi.org/10.1007/s11899-021-00631-7

7. Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 2022; 12(3): 47.

http://doi.org/10.1038/s41408-022-00645-1

8. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, et al. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 2022; 63(3): 710-721. http://doi.org/10.1080/10428194.2021.1992763

9. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N et al. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2022; 28(6): 307.e1-307.e8.

http://doi.org/10.1016/j.jtct.2022.03.020

10. Toor SH, Satti TM, Iftikhar R, Mahmood SK, Shamshad GU, Rehman JU. Bortezomib-based Triplet Regimens for Remission Induction in Multiple Myeloma. J Coll Physicians Surg Pak 2020; 30(5): 527-531.

http://doi.org/10.29271/jcpsp.2020.05.527

11. Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical manual. Geneva: World Health Organization; 1991.

12. Ravi G, Gonsalves WI. Current diagnosis, risk stratification and treatment paradigms in newly diagnosed multiple myeloma. Cancer Treat Res Commun. 2021; 29(3): 100444.

http://doi.org/10.1016/j.ctarc.2021.100444

13. Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, et al. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J 2023; 13(1): 112.

http://doi.org/10.1038/s41408-023-00882-y

14. Rampotas A, Djebbari F, Panitsas F, Facchin G, Corso A, Derudas D et al. Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients. Eur J Haematol 2021; 106(4): 563-573. http://doi.org/10.1111/ejh.13588

15. Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D, et al. Experts' consensus on the definition and management of high risk multiple myeloma. Front Oncol 2023; 12(3): 1096852.

http://doi.org/10.3389/fonc.2022.1096852

16. Halacoglu A. Relationship between firstline treatment response and bone marrow fibrosis in newly diagnosed multiple myeloma. J Hematol Allied Sci 2021; 1: 107-110.

http://doi.org/10.25259/JHAS_30_2021

17. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017; 389(10068): 519-527. http://doi.org/10.1016/S0140-6736(16)31594-X

18. Huijuan W, Guangzhong Y, Yuan J, Chuanying G, Huixing Z, Wenming C. VRD versus VCD induction chemotherapy followed by autologous stem cell transplantation in newly diagnosed multiple myeloma. J Cap Med 2021; 42(4): 615-622.

19. Sidana S, Kumar S, Fraser R, Estrada-Merly N, Giralt S, Agarwal V, et al. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplant Cell Ther 2022; 28(2): 83.e1-83.e9.

http://doi.org/10.1016/j.jtct.2021.10.022

20. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012; 119(19): 4375-82.

http://doi.org/10.1182/blood-2011-11-395749

21. Utervall K, Borg Bruchfeld J, Gran C, Walinder G, Mansson R, Lund J et al. Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. Eur J Haematol 2019; 103(3): 247-254. http://doi.org/10.1111/ejh.13280